Innodata Inc vs Stryker Corporation — how do they compare? Innodata Inc trades at $61.34 (market cap $2.05B), while Stryker Corporation trades at $346.82 (market cap $133.54B). The key difference: Stryker Corporation is far larger — about 65.1× Innodata Inc's market cap, and Stryker Corporation pays a 1.01% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| INOD | SYK | |
|---|---|---|
Market Cap | $2.05B | $133.54B |
Sector | Technology | Technology |
52-Week High | $121.50 | $394.34 |
52-Week Low | $34.45 | $282.58 |
Enterprise Value | $1.80B | $145.01B |
Dividend Yield | — | 1.01% |
Signals from Pluang's Aura AI — not financial advice
INOD trades at $61.47, down 1.21% today, but maintains strong technical support at $60-$62 levels with bullish oscillators and mixed moving averages. The company demonstrates robust fundamental performance with 58% year-over-year revenue growth in Q2 2026, beating earnings estimates for three consecutive quarters, and expanding profit margins to 14.66%. Recent AI-driven business developments and strong analyst coverage support the positive momentum.
INOD presents a compelling growth opportunity with accelerating AI services demand and consistent earnings outperformance, though premium valuation metrics (P/E 48.6, P/S 6.8) warrant caution. Key risks include customer concentration and competitive pressures in the rapidly evolving AI sector. Analyst consensus remains bullish with a $130 price target representing 111% upside potential from current levels.
Stryker (SYK) trades at $347.21, up 0.4% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, including a 9% organic sales growth in Q2 2026 and a net income margin of 14.43%. Recent news highlights recovery from a cybersecurity incident and the launch of Mako RPS, expanding its robotic surgery portfolio. Analyst consensus is overwhelmingly positive, with 74% recommending Buy and a price target of $379.44.
The outlook for SYK is favorable, driven by robust earnings growth and strategic product launches. Key risks include cybersecurity vulnerabilities and margin pressures from tariffs. With no sell ratings and strong institutional support, the stock presents a compelling opportunity for growth-oriented investors, though monitoring quarterly execution remains critical.
Trailing returns across standard periods
Latest headlines on both assets
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →